PBE Dynamic Biotech &Genome
- Health & Biotech Equities
Alternative ETFs in the Health & Biotech Equities Category
|Type||Ticker||Expense Ratio||Assets||Avg. Daily Vol||YTD Return|
|Most Liquid (Volume)|
|Top YTD Performer|
The index is comprised of stocks of U.S. biotechnology and genome companies. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Realtime Rating Summary
PBE is a passive ETF that seeks to replicate Dynamic Biotechnology & Genome Intellidex Index. The index is comprised of stocks of U.S. biotechnology and genome companies. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
The adjacent table gives investors an individual Realtime Rating for PBE on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.
PBE In-Depth Analysis
The following tables and charts contain in-depth metrics for this ETF and compare it to similar peer ETFs within its ETFdb Category.
PBE HoldingsFilings Data as of: Feb 02, 2016
Top Ten Holdings
AMGN 6.42%Amgen Inc
BIIB 6.40%Biogen Inc
ALXN 5.49%Alexion Pharmaceuticals Inc
GILD 5.28%Gilead Sciences Inc
BMRN 5.27%Biomarin Pharmaceutical Inc
REGN 5.12%Regeneron Pharmaceuticals Inc
VRTX 4.68%Vertex Pharmaceuticals Inc
INCY 4.15%Incyte Corp
INVA 4.13%Innoviva Inc
ACOR 3.61%Acorda Therapeutics Inc
This section compares how balanced and deep this ETF is relative to the peer group ETFdb Category.
Market Cap Breakdown
Market Tier Breakdown
PBE Expenses & Fees
This section compares the cost efficiency of this ETF to peers in the same ETFdb Category.
Expenses Ratio Analysis
Commission Free Trading
This ETF is not currently available for commission free trading on any platforms.
Category Commission Free Trading
There are 3 other ETFs in the Health & Biotech Equities ETFdb Category that are also eligible for commission free trading:
This section shows how this ETF has performed relative to its peer group ETFdb Category.
The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.
The following chart also includes the option to compare the performance of PBE relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.
This section shows how the volatility of this ETF compares to the peer group ETFdb Category.
- 20 Day MA: $38.29
- 60 Day MA: $45.33
- MACD 15 Period: -1.66
- MACD 100 Period: -10.60
- Williams % Range 10 Day: 65.55
- Williams % Range 20 Day: 76.70
- RSI 10 Day: 34
- RSI 20 Day: 33
- RSI 30 Day: 35
- Ultimate Oscillator: 43
- Lower Bollinger (10 Day): $33.69
- Upper Bollinger (10 Day): $39.28
- Lower Bollinger (20 Day): $33.94
- Upper Bollinger (20 Day): $42.65
- Lower Bollinger (30 Day): $32.18
- Upper Bollinger (30 Day): $49.28
Support & Resistance
- Support Level 1: $34.97
- Support Level 2: $34.06
- Resistance Level 1: $36.34
- Resistance Level 2: $36.80
- Stochastic Oscillator %D (1 Day): 62.37
- Stochastic Oscillator %D (5 Day): 41.33
- Stochastic Oscillator %K (1 Day): 49.29
- Stochastic Oscillator %K (5 Day): 31.05
Latest PBE News
Best & Worst Weekly Performers January 11th Edition
The Best Performing ETFs of 2013
7 ETF Types To Be Thankful For
2014 Morningstar, Inc. All Rights Reserved. The information contained herein: ( 1 ) is proprietary to Morningstar and/or its content providers; ( 2 ) may not be copied or distributed; and ( 3 ) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.